Positive News Sentiment NASDAQ:BDSX Biodesix - BDSX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.72 -0.01 (-0.58%) (As of 03/28/2023 05:12 PM ET) Add Compare Share Share Today's Range$1.67▼$1.7750-Day Range$1.52▼$2.5052-Week Range$0.96▼$3.00Volume42,073 shsAverage Volume119,715 shsMarket Capitalization$134.11 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Biodesix MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside397.1% Upside$8.50 Price TargetShort InterestHealthy0.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$149,600 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.81) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector231st out of 1,002 stocksMedical Laboratories Industry8th out of 26 stocks 3.5 Analyst's Opinion Consensus RatingBiodesix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Biodesix has a forecasted upside of 397.1% from its current price of $1.71.Amount of Analyst CoverageBiodesix has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.95% of the float of Biodesix has been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently increased by 2.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBiodesix does not currently pay a dividend.Dividend GrowthBiodesix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDSX. Previous Next 3.3 News and Social Media Coverage News SentimentBiodesix has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biodesix this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for BDSX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows2 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biodesix insiders have bought 241.09% more of their company's stock than they have sold. Specifically, they have bought $149,600.00 in company stock and sold $43,859.00 in company stock.Percentage Held by Insiders49.80% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biodesix are expected to grow in the coming year, from ($0.81) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biodesix is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biodesix is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiodesix has a P/B Ratio of 6.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biodesix (NASDAQ:BDSX) StockBiodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.Read More Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Email Address BDSX Stock News HeadlinesMarch 15, 2023 | finance.yahoo.comBullish Biodesix, Inc. (NASDAQ:BDSX) insiders filled their treasuries with US$34m worth of stock over last yearMarch 8, 2023 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q4 2022 Earnings Call TranscriptMarch 28, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 6, 2023 | finance.yahoo.comBiodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and HighlightsMarch 6, 2023 | finance.yahoo.comBiodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue EstimatesFebruary 21, 2023 | finance.yahoo.comBiodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023February 16, 2023 | finance.yahoo.comEven after rising 15% this past week, Biodesix (NASDAQ:BDSX) shareholders are still down 39% over the past yearDecember 19, 2022 | finance.yahoo.comBiodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® TestMarch 28, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …December 16, 2022 | finance.yahoo.comBiodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of DirectorsDecember 12, 2022 | finance.yahoo.comBiodesix Ranked Top Proteomics Solutions Company by Life Sciences Review MagazineNovember 21, 2022 | finance.yahoo.comBiodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesNovember 17, 2022 | finance.yahoo.comBiodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common StockNovember 16, 2022 | finance.yahoo.comBiodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 MillionNovember 16, 2022 | finance.yahoo.comBiodesix Announces Proposed Public Offering of Common StockNovember 10, 2022 | finance.yahoo.comBiodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNovember 9, 2022 | finance.yahoo.comBiodesix Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 3, 2022 | finance.yahoo.comBiodesix Announces Third Quarter 2022 Results and HighlightsOctober 20, 2022 | finance.yahoo.comBiodesix to Report Third Quarter 2022 Financial Results on November 3, 2022October 17, 2022 | finance.yahoo.comBoulder's Biodesix snags $20M contract, plans move to larger space in LouisvilleOctober 17, 2022 | businesswire.comBiodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions - Business WireOctober 17, 2022 | finance.yahoo.comBiodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing SolutionsOctober 14, 2022 | businesswire.comInsights on the Liquid Biopsy Global Market to 2028 - Featuring Biocept, Epigenomics, Exosome Diagnostics and Lariat Biosciences Among Others - ResearchAndMarkets.com - Business WireOctober 13, 2022 | seekingalpha.comBiodesix expects Q3 revenue above the consensus - Seeking AlphaOctober 12, 2022 | streetinsider.comBiodesix Announces Preliminary Revenue for Third Quarter 2022 - StreetInsider.comOctober 12, 2022 | businesswire.comBiodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs - Business WireOctober 12, 2022 | finance.yahoo.comBiodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening ProgramsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Email Address BDSX Company Calendar Last Earnings3/06/2023Today3/28/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BDSX CUSIPN/A CIK1439725 Webwww.biodesix.com Phone303-417-0500FaxN/AEmployees218Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.50 High Stock Price Forecast$10.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+394.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,450,000.00 Net Margins-171.27% Pretax Margin-171.27% Return on Equity-741.60% Return on Assets-83.92% Debt Debt-to-Equity Ratio1.21 Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual Sales$38.21 million Price / Sales3.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book6.37Miscellaneous Outstanding Shares77,970,000Free Float39,143,000Market Cap$134.11 million OptionableNot Optionable Beta1.50 Key ExecutivesMr. Scott Hutton (Age 50)Pres, CEO & Director Comp: $586.3kMs. Robin Harper Cowie (Age 42)CFO, Sec. & Treasurer Comp: $349.05kMr. Ryan H. Siurek (Age 50)Chief Accounting Officer Comp: $294.87kDr. Heinrich RöderFounder & CTODr. Robert W. Georgantas III (Age 51)Ph.D., Chief Scientific Officer Mr. Jeffrey A. BojarVP of Legal and Regulatory AffairsMr. Matt StaufferVP of SalesDr. Paul J. BeresfordChief Bus. OfficerDr. Gary Anthony Pestano Ph.D. (Age 55)Chief Devel. Officer Ms. Bobbi CoffinChief Growth OfficerMore ExecutivesKey CompetitorsCelcuityNASDAQ:CELCSera PrognosticsNASDAQ:SERAPersonalisNASDAQ:PSNLEnzo BiochemNYSE:ENZDermTechNASDAQ:DMTKView All CompetitorsInsiders & InstitutionsAIGH Capital Management LLCBought 6,093,475 shares on 2/16/2023Ownership: 14.477%Endurant Capital Management LPSold 5,706 shares on 2/15/2023Ownership: 0.296%Millennium Management LLCSold 10,260 shares on 2/15/2023Ownership: 0.256%CI Private Wealth LLCBought 24,747 shares on 2/15/2023Ownership: 0.059%CIBC Private Wealth Group LLCBought 13,100 shares on 2/13/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions BDSX Stock - Frequently Asked Questions Should I buy or sell Biodesix stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDSX shares. View BDSX analyst ratings or view top-rated stocks. What is Biodesix's stock price forecast for 2023? 4 equities research analysts have issued 1 year target prices for Biodesix's stock. Their BDSX share price forecasts range from $7.00 to $10.00. On average, they expect the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 394.2% from the stock's current price. View analysts price targets for BDSX or view top-rated stocks among Wall Street analysts. How have BDSX shares performed in 2023? Biodesix's stock was trading at $2.30 on January 1st, 2023. Since then, BDSX stock has decreased by 25.2% and is now trading at $1.72. View the best growth stocks for 2023 here. When is Biodesix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our BDSX earnings forecast. How were Biodesix's earnings last quarter? Biodesix, Inc. (NASDAQ:BDSX) issued its earnings results on Monday, March, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The business earned $9.61 million during the quarter, compared to analyst estimates of $10.70 million. Biodesix had a negative net margin of 171.27% and a negative trailing twelve-month return on equity of 741.60%. During the same quarter in the previous year, the company earned ($0.49) EPS. What guidance has Biodesix issued on next quarter's earnings? Biodesix issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $52.00 million-$55.00 million, compared to the consensus revenue estimate of $52.51 million. When did Biodesix IPO? (BDSX) raised $76 million in an IPO on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. What is Biodesix's stock symbol? Biodesix trades on the NASDAQ under the ticker symbol "BDSX." Who are Biodesix's major shareholders? Biodesix's stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (14.48%), Birchview Capital LP (11.97%), HighTower Advisors LLC (0.32%), Endurant Capital Management LP (0.30%), Millennium Management LLC (0.26%) and Legato Capital Management LLC (0.08%). Insiders that own company stock include Charles M Watts, Gary Anthony Pestano, Hany Massarany, Jack W Schuler, John Patience, Kieran O'kane, Matthew Strobeck, Robert William Georgantas III, Robin Harper Cowie, Ryan H Siurek and Scott Hutton. View institutional ownership trends. How do I buy shares of Biodesix? Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biodesix's stock price today? One share of BDSX stock can currently be purchased for approximately $1.72. How much money does Biodesix make? Biodesix (NASDAQ:BDSX) has a market capitalization of $134.11 million and generates $38.21 million in revenue each year. The company earns $-65,450,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. How many employees does Biodesix have? The company employs 218 workers across the globe. How can I contact Biodesix? The official website for the company is www.biodesix.com. The company can be reached via phone at 303-417-0500 or via email at chris.brinzey@westwicke.com. This page (NASDAQ:BDSX) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.